Clinical trial NCT01239771: A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects
Official title: A Phase I, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of TC-5214 Given as Multiple Ascending Oral Doses in Medically Stable Elderly Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
Keywords: Safety
tolerability
healthy
stable disease
oral
tablet
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-11-11
Enrollment: 32
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to assess safety, tolerability and pharmacokinetics of TC-5214 in medically stable elderly subjects following multiple oral doses.


Eligibility criteria: Inclusion Criteria:

* Medically stable male and female subjects aged greater than or equal to 65 years with suitable veins for cannulation or repeated venipuncture. Subjects may have controlled chronic diseases such as hypertension, type 2 diabetes, osteoarthritis, stable chronic obstructive pulmonary disease, mild or moderate renal insufficiency (Estimated glomerular filtration rate (eGFR) per the Modified Diet in Renal Disease \[MDRD\] formula \>50 mL/min/1.73 m2), rhinitis etc. as long as there has not been any significant changes in their medical condition or medications for the preceding 6 weeks. Classification of renal impairment will be based using an MDRD equation
* Male subjects who are sexually active must use a condom and their partner if of childbearing potential must use a reliable method of contraception from the first dose of investigational product until 3 months after their last dose
* Have a body mass index (BMI) between 19 and 32 kg/m2 and weigh at least 50 kg

Exclusion Criteria:

* History of any clinically significant medical, neurologic or psychiatric disease or disorder (other than those previously defined as acceptable for this population, see inclusion criterion 1) which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject's ability to participate in the study: This includes seizure activity and repeated episodes of major depression
* Significant cardiovascular or cerebrovascular disease such as: a history of acute coronary syndrome; angina that has been symptomatic in the last 6 months; significant symptomatic arrhythmia; a stroke; transient ischemic attack that have occurred in the last 6 months
* History or presence of gastrointestinal or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
* Subjects who have type 2 diabetes must have an HbA1c of less than 8% according to the National Glycohemoglobin Standardization Program (NGSP) at screening
* Significant renal insufficiency as defined by eGFR per the MDRD formula \<50 mL/min/1.73 m2 (individual eGFR measurements will be documented in the protocol).

Primary outcomes:
measure: Incidence of Adverse events
timeFrame: Range of 5 days
measure: Neurological examinations
timeFrame: Range of 5 days
measure: Visual acuity tests
timeFrame: Range of 5 days
measure: Vital signs
timeFrame: Range of 5 days
measure: Physical examinations
timeFrame: Range of 5 days
measure: Laboratory parameters
timeFrame: Range of 5 days
measure: Suicidality as assessed by the Columbia-Suicide Severity Rating Scale
timeFrame: Range of 5 days
measure: Electrocardiograms
timeFrame: Range of 5 days
Secondary outcomes:
measure: Pharmacokinetic variables of TC-5214 by assessment of drug concentrations in plasma
timeFrame: Range of 5 days
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: Hans A Eriksson, MD
role: STUDY_DIRECTOR
affiliation: Quintiles Phase 1
name: Wolfgang Kuhn, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Quintiles Hermelinen
name: Aslak Rautio, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Xu H, Henningsson A, Alverlind S, Tummala R, Toler S, Beaver JS, Al-Huniti N. Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studies. J Clin Pharmacol. 2014 Jun;54(6):707-18. doi: 10.1002/jcph.264. Epub 2014 Jan 16.